Low-dose cytarabine to prevent myeloid leukemia in children with down syndrome: TMD prevention 2007 study

Marius Flasinski, Kira Scheibke, Martin Zimmermann, Ursula Creutzig, Katarina Reinhardt, Femke Verwer, Valerie De Haas, Vincent H.J. Van Der Velden, Christine Von Neuhoff, C. Michel Zwaan, Dirk Reinhardt, Jan Henning Klusmann

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

20 Citaten (Scopus)

Samenvatting

Approximately 5% to 10% of children with Down syndrome (DS) are diagnosed with transient myeloproliferative disorder (TMD). Approximately 20% of these patients die within 6 months (early death), and another 20% to 30% progress to myeloid leukemia (ML-DS) within their first 4 years of life. The aim of the multicenter, nonrandomized, historically controlled TMD Prevention 2007 trial was to evaluate the impact of low-dose cytarabine treatment on survival and prevention of ML-DS in patients with TMD. Patients received cytarabine (1.5 mg/kg for 7 days) in case of TMD-related symptoms at diagnosis (high white blood cell count, ascites, liver dysfunction, hydrops fetalis) or detection of minimal residual disease (MRD) 8 weeks after diagnosis. The 5-year probability of event-free and overall survival of 102 enrolled TMD patients was 72 6 5% and 91 6 3%, respectively. In patients eligible for treatment because of symptoms (n 5 43), we observed a significantly lower cumulative incidence (CI) of early death as compared with symptomatic patients in the historical control (n 5 45) (12 6 5% vs 33 6 7%, PGray 5 .02). None of the asymptomatic patients in the current study suffered early death. However, the treatment of symptomatic or MRD-positive patients did not result in a significantly lower CI of ML-DS (25 6 7% [treated] vs 14 6 7% [untreated], PGray 5 .34 [per protocol analysis]; historical control: 22 6 4%, PGray 5 .55). Thus, low-dose cytarabine treatment helped to reduce TMD-related mortality when compared with the historical control but was insufficient to prevent progression to ML-DS. This trial was registered at EudraCT as #2006-002962-20.

Originele taal-2Engels
Pagina's (van-tot)1532-1540
Aantal pagina's9
TijdschriftBlood Advances
Volume2
Nummer van het tijdschrift13
DOI's
StatusGepubliceerd - 10 jul. 2018
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Low-dose cytarabine to prevent myeloid leukemia in children with down syndrome: TMD prevention 2007 study'. Samen vormen ze een unieke vingerafdruk.

Citeer dit